Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway
International Journal of Oncology · 2025
DOI: 10.3892/ijo.2025.5726 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, 2025. Verfasst von Shiming Tan und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metaboli…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Long non‑coding (lnc)RNAs participate in colorectal cancer (CRC) occurrence and progression. The present study aimed to investigate whether lncRNA ABHD11‑AS1 regulates malignant biological behavior of CRC cells. Bioinformatic analysis, reverse transcription‑quantitative PCR and in situ hybridization revealed that ABHD11‑AS1 expression was decreased in CRC samples and associated with an unfavorable prognosis. ABHD11‑AS1 overexpression significantly decreased proliferation, migration and invasion of CRC cells, whereas ABHD11‑AS1 inhibition had the opposite effects. ABHD11‑AS1 interacted with EGFR to inhibit EGFR phosphorylation and attenuate EGFR/ERK signaling, which in turn suppressed the malignant biological behavior of CRC cells. The tumor suppressor function of ABHD11‑AS1 was attenuated by the EGFR agonist NSC228155. Finally, resveratrol (RSV) inhibited CRC cell proliferation, migration and invasion, which may be associated with RSV‑induced decrease in SPT6 homolog, histone chaperone and transcription elongation factor protein expression and increase in ABHD11‑AS1 transcript levels. ABHD11‑AS1 inhibited the phosphorylation of EGFR and decreased EGFR/ERK signaling by interacting with EGFR, thereby delaying the progression of CRC. The ABHD11‑AS1/EGFR/ERK axis may be a novel therapeutic target for preventing CRC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
- Department of Oncology, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan 410005, P.R. China.
Zitieren
APA
Tan, S., Li, S., Xia, L., Jiang, X., Ren, Z., Peng, Q., Peng, M., Yang, W., Xu, X., Oyang, L., Shen, M., Wang, J., Li, H., Wu, N., Tang, Y., Liao, Q., Lin, J., & Zhou, Y. (2025). Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway. International Journal of Oncology. https://doi.org/10.3892/ijo.2025.5726
Vancouver
Tan S, Li S, Xia L, Jiang X, Ren Z, Peng Q, et al. Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway. International Journal of Oncology. 2025. doi:10.3892/ijo.2025.5726
BibTeX
@article{Tan2025,
author = {Tan, Shiming and Li, Shizhen and Xia, Longzheng and Jiang, Xianjie and Ren, Zongyao and Peng, Qiu and Peng, Mingjing and Yang, Wenjuan and Xu, Xuemeng and Oyang, Linda and Shen, Mengzhou and Wang, Jiewen and Li, Haofan and Wu, Nayiyuan and Tang, Yanyan and Liao, Qianjin and Lin, Jinguan and Zhou, Yujuan},
title = {Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway},
journal = {International Journal of Oncology},
year = {2025},
doi = {10.3892/ijo.2025.5726}
}
EUVIMED